Profits sharply down at at DSM
date:Feb 21, 2013
at 22.1%. Full year organic growth was 2% driven by volumes and stable prices. EBITDA was 793 million and increased by 8% as a result of continued growth in advanced forms, premixes and nutritional lipids and contributions from acquisitions.

07/14 20:15